Barton DL et al., 2013-08-21: Phase III trial N07C2 of American ginseng 2000 mg/day versus placebo in 364 fatigued cancer survivors. The 4-week primary endpoint was not met (P = .07); the difference reached significance only at 8 weeks (P = .003).
A statistically significant difference was seen at 8 weeks with a change score of 20 (SD = 27) for the ginseng group and 10.3 (SD = 26.1) for the placebo group (P = .003).
Abstract, Results
Barton DL et al., 2013-08-21: Phase III trial N07C2 of American ginseng 2000 mg/day versus placebo in 364 fatigued cancer survivors. The 4-week primary endpoint was not met (P = .07); the difference reached significance only at 8 weeks (P = .003). Study type: randomized trial.
